1. Epigenetic regulation of PRAME in acute myeloid leukemia is different compared to CD34+ cells from healthy donors: Effect of 5-AZA treatment
- Author
-
Carmen Herrero-Sánchez, Silvia Gutierrez-Cosio, Carlos Santamaría, J F San Miguel, Luis Ignacio Sánchez-Abarca, Belén Blanco, C Cañizo, Teresa Caballero-Velázquez, L. de la Rica, Laura Ciudad, Cristina Calderón, José A. Pérez-Simón, Soraya Carrancio, and Esteban Ballestar
- Subjects
Antimetabolites, Antineoplastic ,Cancer Research ,Myeloid ,Azacitidine ,CD34 ,Antigens, CD34 ,Blood Donors ,Bone Marrow Cells ,Epigenesis, Genetic ,Antigens, Neoplasm ,hemic and lymphatic diseases ,Biomarkers, Tumor ,Humans ,Medicine ,Epigenetics ,Cells, Cultured ,PRAME ,Gene Expression Regulation, Leukemic ,business.industry ,Stem Cells ,Myeloid leukemia ,Hematology ,Leukemia, Myeloid, Acute ,medicine.anatomical_structure ,Oncology ,Health ,Cytogenetic Analysis ,DNA methylation ,Immunology ,CpG Islands ,Stem cell ,business ,medicine.drug - Abstract
PRAME is a tumor associated antigen (TAA) of particular interest since it is widely expressed by lymphoid and myeloid malignancies. Several studies have associated high PRAME RNA levels with good prognosis in acute myeloid leukemia (AML). PRAME expression is regulated at the epigenetic level. For this reason inhibitors of DNA methylation, such as 5-azacytidine, can modulate the expression of this TAAs. In the current study we analyzed the effect of 5-azaC on the expression of PRAME in blasts versus CD34+ cells from healthy donors in an attempt to increase its expression, thus inducing a potential target for therapeutic strategies.
- Published
- 2012
- Full Text
- View/download PDF